Ignyta, Inc. (RXDX)

Oncology Corporate Profile

Stock Performance

9.1500
0.0000

HQ Location

11095 Flintkote Avenue, Suite D
San Diego, CA 92121

Company Description

Ignyta, Inc. is a trailblazing biotechnology company catalyzing personalized medicine in cancer. We are pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. We achieve this goal by leveraging our proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.

Website: http://www.ignyta.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RXDX-105multiple tyrosine kinase inhibitorVarious cancer typesII
entrectinib / RXDX-101tyrosine kinase inhibitorVarious cancer typesII

View additional information on product candidates here »

Pipeline image

Source


http://www.ignyta.com

Recent News Headlines

Ignyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly

3/23/2017 08:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that it is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program.

IGNYTA, INC. Financials

3/18/2017 05:00 pm

Ignyta Announces Full Year 2016 Company Highlights and Financial Results

3/14/2017 08:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the full year ended December 31, 2016.

Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific

3/3/2017 02:00 pm

[Marketwired] - Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., , a biotechnology company focused ...

Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery

2/9/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib—the company’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions—were published in the journal Cancer Discovery.

Ignyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

2/8/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017, at 11:30 a.m.

Ignyta to Present at 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 35th Annual J.P.

Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals, Inc., to Board of Directors

12/12/2016 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced the appointment of Mr. Steven L. Hoerter to its board of directors, effective December 8, 2016.

Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting

12/2/2016 09:03 am

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib in overcoming resistance to TRK inhibition during a late-breaking oral plenary presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

Ignyta Announces Compelling Phase 1/1b Clinical Data on RXDX-105, Its VEGFR-Sparing RET Inhibitor, at the 2016 EORTC-NCI-AACR Annual Meeting

12/1/2016 09:01 am

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced data from an ongoing Phase 1/1b study of RXDX-105—Ignyta’s VEGFR-sparing, potent RET inhibitor—at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany, highlighting RXDX-105’s clinical activity in patients harboring RET molecular alterations, with five out of ...